Giant Cell Arteritis
Rapid advances propel polymyalgia rheumatica care and research
The field of rheumatology is constantly in flux.
‘Tsunami of effort’ brings biologics to the forefront in giant cell arteritis, PMR
Reducing glucocorticoid use in the treatment of giant cell arteritis and polymyalgia rheumatica — due to the steroid’s host of related toxicities and adverse effects — has long been a goal for rheumatologists.
FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.
VIDEO: Age risk differs widely between vasculitis types
In this video, Rula Hajj-Ali, MD discusses the risk factors for vasculitis.
VIDEO: Many new developments in vasculitis treatment
In this video, Rula Hajj-Ali, MD discusses the latest developments in the study and treatment of vasculitis.
Alaska Native, American Indian populations show ‘high’ rates of ANCA-associated vasculitis
WASHINGTON — Alaska Native and American Indian populations demonstrate notably higher prevalences of ANCA-associated vasculitis vs. white patients, according to data presented at ACR Convergence 2024.
Upadacitinib shows ‘broad efficacy’ across patient subgroups in giant cell arteritis
WASHINGTON — Upadacitinib 15 mg is superior to placebo for achieving sustained remission in giant cell arteritis across patient subgroups based on age, sex and glucocorticoid experience, according to data presented at ACR Convergence 2024.
Anticoagulant therapy reduces risks for vision loss, stroke in giant cell arteritis
Patients with giant cell arteritis who use anticoagulants demonstrate lower risks for vision loss, stroke and other cranial ischemic complications, according to data published in Annals of the Rheumatic Diseases.
‘It’s going to be imaging’: MRI, ultrasound to streamline giant cell arteritis diagnosis
SAN DIEGO — Imaging techniques are poised to streamline the diagnosis of giant cell arteritis in the United States, after gaining traction elsewhere, according to a speaker at the 2024 Congress of Clinical Rheumatology West.
'The disease that drives us crazy': Diagnosing GCA vs polymyalgia rheumatica
SAN DIEGO — Diagnosing giant cell arteritis and polymyalgia rheumatica can “fascinate” and cause “trepidation” in equal measure due to their similarities and complications, said a speaker at the 2024 Congress of Clinical Rheumatology West.